Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free SYRE Stock Alerts

Spyre Therapeutics (SYRE) Financials

Spyre Therapeutics logo
$75.10 -0.55 (-0.73%)
As of 03:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Spyre Therapeutics

Annual Income Statements for Spyre Therapeutics

This table shows Spyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -12 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Consolidated Net Income / (Loss)		 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Net Income / (Loss) Continuing Operations		 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Total Pre-Tax Income 		-11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Total Operating Income		 -11 -22 -28 -45 -80 -81 -66 -85 -242 -209 -210
Total Gross Profit		 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00 0.00
Total Revenue		 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00 0.00
Operating Revenue		 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 27 33 49 80 81 84 87 243 209 210
Selling, General & Admin Expense		 5.95 8.39 10 13 16 22 27 29 40 46 48
Research & Development Expense		 11 18 23 37 65 60 57 59 220 163 172
Other Operating Expenses / (Income)		 - - - - - - 0.00 0.00 -16 0.00 -10
Total Other Income / (Expense), net		 0.02 0.21 0.44 1.12 2.08 0.59 -0.01 0.84 -97 0.60 54
Interest & Investment Income		 0.02 0.24 0.48 1.17 2.14 0.59 0.11 0.84 6.15 21 25
Other Income / (Expense), net		 -0.00 -0.04 -0.04 -0.06 -0.06 -0.01 -0.12 0.00 -103 -21 29
Income Tax Expense		 - - - - 0.00 0.00 0.14 -0.14 -0.03 0.05 -0.02
Basic Earnings per Share		 ($19.21) ($2.22) ($1.80) ($2.13) ($2.45) ($1.52) $0.00 $0.00 ($1,114.33) $0.00 ($160.02)
Weighted Average Basic Shares Outstanding		 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 2.63M 0.00 7.34M 0.00 64.42M
Diluted Earnings per Share		 ($19.21) ($2.22) ($1.80) ($2.13) ($2.45) ($1.52) $0.00 $0.00 ($1,114.33) $0.00 ($160.02)
Weighted Average Diluted Shares Outstanding		 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 2.63M 0.00 7.34M 0.00 64.42M
Weighted Average Basic & Diluted Shares Outstanding		 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 65.74M 65.40M 36.15M 60.28M 78.54M

Quarterly Income Statements for Spyre Therapeutics

This table shows Spyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -40 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69
Consolidated Net Income / (Loss)		 -40 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69
Net Income / (Loss) Continuing Operations		 -40 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69
Total Pre-Tax Income 		-40 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69
Total Operating Income		 -18 -46 -48 -44 -55 -61 -54 -42 -57 -57 -46
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 18 46 48 44 55 61 54 42 57 57 46
Selling, General & Admin Expense		 8.58 14 13 12 11 11 12 12 12 13 15
Research & Development Expense		 24 34 35 33 45 50 42 40 45 45 60
Other Operating Expenses / (Income)		 -15 - - 0.00 0.00 - 0.00 -10 0.00 - -30
Total Other Income / (Expense), net		 -22 -17 3.95 5.31 -14 4.96 8.78 5.22 46 -5.36 -23
Interest & Investment Income		 1.25 4.13 4.43 5.92 5.18 5.78 6.49 5.87 5.38 7.14 7.00
Other Income / (Expense), net		 -23 -21 -0.48 -0.61 -19 -0.82 2.29 -0.66 40 -12 -30
Income Tax Expense		 0.00 - 0.03 0.00 0.02 0.00 -0.02 0.00 0.00 - 0.00
Basic Earnings per Share		 $0.86 ($8.61) ($58.58) $0.00 $0.00 ($1.19) ($48.50) ($39.73) ($12.09) ($59.70) $0.00
Weighted Average Basic Shares Outstanding		 4.29M 7.34M 37.12M 0.00 0.00 47.49M 60.63M 60.70M 60.78M 64.42M 0.00
Diluted Earnings per Share		 $0.86 ($8.61) ($58.58) $0.00 $0.00 ($1.19) ($48.50) ($39.73) ($12.09) ($59.70) ($0.74)
Weighted Average Diluted Shares Outstanding		 4.29M 7.34M 37.12M 0.00 0.00 47.49M 60.63M 60.70M 60.78M 64.42M 0.00
Weighted Average Basic & Diluted Shares Outstanding		 4.05M 36.15M 40.28M 50.79M 51.43M 60.28M 60.35M 60.40M 77.59M 78.54M 86.84M

Annual Cash Flow Statements for Spyre Therapeutics

This table details how cash moves in and out of Spyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 27 18 -35 9.64 -1.71 71 -75 19 153 -100 -3.70
Net Cash From Operating Activities		 -11 -19 -25 -32 -66 -76 -54 -80 -100 -157 -169
Net Cash From Continuing Operating Activities		 -11 -19 -25 -32 -66 -76 -54 -80 -100 -157 -169
Net Income / (Loss) Continuing Operations		 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Consolidated Net Income / (Loss)		 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Depreciation Expense		 0.09 0.13 0.25 0.29 0.42 1.00 1.58 1.57 0.74 0.00 0.00
Amortization Expense		 0.00 0.10 0.08 -0.59 -0.82 0.07 0.97 0.07 -2.10 -11 -8.09
Non-Cash Adjustments To Reconcile Net Income		 1.56 1.18 2.50 5.25 5.86 6.59 7.70 7.10 243 67 -0.03
Changes in Operating Assets and Liabilities, net		 -1.33 1.45 -0.20 7.20 7.10 -2.54 1.83 -5.07 -2.88 -4.53 -5.93
Net Cash From Investing Activities		 -4.01 -12 -23 -15 -1.74 -7.60 -23 57 -108 -353 -143
Net Cash From Continuing Investing Activities		 -4.01 -12 -23 -15 -1.74 -7.60 -23 57 -108 -353 -143
Purchase of Investments		 -3.77 -20 -64 -62 -92 -129 -133 -40 -167 -599 -522
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.00 0.48 0.00 0.00
Divestitures		 - - - - - - 0.00 0.00 18 0.00 7.00
Sale and/or Maturity of Investments		 - 8.45 42 47 92 126 111 97 40 246 372
Net Cash From Financing Activities		 42 49 12 57 66 155 1.39 43 361 411 309
Net Cash From Continuing Financing Activities		 42 49 12 57 66 155 1.39 43 361 411 309
Repayment of Debt		 - - - - - - - - -0.02 0.00 0.00
Issuance of Common Equity		 0.02 49 0.83 3.02 66 155 1.90 43 367 413 314
Other Financing Activities, net		 - - 11 54 -0.03 -0.02 -0.51 -0.42 -5.79 -1.84 -5.41
Other Net Changes in Cash		 - - - - - 0.05 - -0.11 0.03 -0.00 0.00

Quarterly Cash Flow Statements for Spyre Therapeutics

This table details how cash moves in and out of Spyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -145 97 39 -182 26 18 -41 33 -17 21 11
Net Cash From Operating Activities		 -35 -31 -29 -62 -29 -37 -41 -47 -37 -45 -57
Net Cash From Continuing Operating Activities		 -35 -31 -29 -62 -29 -37 -41 -47 -37 -45 -57
Net Income / (Loss) Continuing Operations		 -40 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69
Consolidated Net Income / (Loss)		 -40 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69
Amortization Expense		 -0.49 -1.71 -2.42 -3.56 -3.00 -2.42 -2.64 -2.01 -1.35 -2.09 -2.06
Non-Cash Adjustments To Reconcile Net Income		 12 36 14 9.31 32 11 6.99 1.21 -31 22 13
Changes in Operating Assets and Liabilities, net		 -5.92 -1.86 3.47 -29 10 11 -0.57 -9.04 5.94 -2.27 0.24
Net Cash From Investing Activities		 -98 -35 -105 -121 43 -171 -0.06 79 25 -247 57
Net Cash From Continuing Investing Activities		 -98 -35 -105 -121 43 -171 -0.06 79 25 -247 57
Purchase of Investments		 -113 -54 -153 -178 -35 -233 -71 -35 -74 -342 -81
Divestitures		 15 - - - - - 0.00 - - - 30
Sale and/or Maturity of Investments		 - 19 48 58 78 63 71 107 99 94 108
Net Cash From Financing Activities		 -13 164 172 0.36 13 226 0.13 0.73 -4.64 313 12
Net Cash From Continuing Financing Activities		 -13 164 172 0.36 13 226 0.13 0.73 -4.64 313 12
Issuance of Common Equity		 0.11 367 174 0.50 13 395 0.22 0.73 0.49 313 12
Other Financing Activities, net		 - -5.79 -1.43 - -0.08 -0.33 -0.09 - -5.13 -0.07 -0.17

Annual Balance Sheets for Spyre Therapeutics

This table presents Spyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 39 67 56 78 83 162 110 71 342 608 778
Total Current Assets		 38 66 55 77 75 150 99 62 342 608 778
Cash & Equivalents		 29 48 13 22 19 90 15 35 189 89 86
Short-Term Investments		 3.77 16 37 52 53 56 78 21 150 514 671
Prepaid Expenses		 0.91 1.71 1.61 2.16 2.56 3.52 4.95 6.17 2.25 5.39 21
Plant, Property, & Equipment, net		 0.35 0.60 0.85 1.02 2.39 5.64 4.55 3.22 0.00 0.00 0.00
Total Noncurrent Assets		 0.02 0.04 0.23 0.05 6.29 6.19 6.49 5.67 0.33 0.01 0.00
Total Liabilities & Shareholders' Equity		 39 67 56 78 83 162 110 71 342 608 778
Total Liabilities		 2.55 4.10 5.74 10 23 22 26 21 73 91 63
Total Current Liabilities		 2.52 3.97 5.63 10 18 16 20 15 32 54 59
Accounts Payable		 0.18 0.17 0.39 0.66 3.15 2.25 3.32 0.68 17 1.27 8.92
Accrued Expenses		 2.35 3.73 5.22 9.58 15 14 14 13 13 28 27
Other Current Liabilities		 - - - - 0.35 0.32 0.44 0.63 1.39 25 23
Total Noncurrent Liabilities		 0.03 0.13 0.11 0.07 4.74 5.34 5.84 6.18 41 37 3.86
Other Noncurrent Operating Liabilities		 - - - - 4.71 5.13 4.61 4.00 41 37 3.86
Other Noncurrent Nonoperating Liabilities		 0.03 0.13 0.11 0.07 0.03 0.21 0.02 - - - 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -22 63 50 67 60 140 84 50 184 518 715
Total Preferred & Common Equity		 -22 63 50 67 60 140 84 50 184 518 715
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 185 156 156
Total Common Equity		 -22 63 50 67 60 140 84 50 -0.91 362 559
Common Stock		 1.37 108 123 184 255 416 426 476 763 1,334 1,686
Retained Earnings		 -24 -45 -73 -117 -195 -276 -342 -426 -764 -972 -1,128
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.00 -0.10 -0.03 0.05 0.01 -0.02 -0.05 0.30 0.18 0.87

Quarterly Balance Sheets for Spyre Therapeutics

This table presents Spyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 92 52 244 207 488 436 421 570 539 505 764
Total Current Assets		 82 44 240 206 487 436 421 570 539 505 764
Cash & Equivalents		 39 35 235 91 228 45 72 48 82 65 97
Short-Term Investments		 35 3.24 0.00 113 257 381 343 516 445 421 644
Prepaid Expenses		 7.87 5.57 2.88 2.19 2.63 9.74 6.85 4.95 12 18 22
Plant, Property, & Equipment, net		 3.56 3.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 5.79 4.65 3.64 1.32 0.33 0.33 0.01 0.01 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 92 52 244 207 488 436 421 570 539 505 764
Total Liabilities		 24 19 254 66 82 62 94 87 83 50 93
Total Current Liabilities		 18 13 232 45 43 22 58 71 83 46 85
Accounts Payable		 4.18 2.06 24 22 19 14 20 6.24 3.74 11 5.74
Accrued Expenses		 12 9.67 28 16 22 5.68 13 22 19 24 29
Other Current Liabilities		 0.59 0.61 179 7.51 2.59 2.64 25 43 60 11 50
Total Noncurrent Liabilities		 6.33 6.16 21 21 39 40 36 16 0.00 3.23 7.98
Other Noncurrent Operating Liabilities		 4.16 3.82 0.00 21 39 40 36 16 0.00 3.23 6.69
Other Noncurrent Nonoperating Liabilities		 0.00 - 19 - - - - - - - 1.29
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 68 34 -207 -245 152 374 327 483 456 455 671
Total Preferred & Common Equity		 68 34 -207 -245 152 374 327 483 456 455 671
Preferred Stock		 0.00 0.00 0.00 0.00 185 156 156 156 156 156 156
Total Common Equity		 68 34 -207 -245 -33 219 172 327 300 299 515
Common Stock		 475 478 454 456 776 1,066 1,086 1,343 1,353 1,364 1,712
Retained Earnings		 -407 -444 -661 -701 -808 -847 -916 -1,017 -1,054 -1,065 -1,197
Accumulated Other Comprehensive Income / (Loss)		 -0.18 -0.01 0.01 -0.13 -0.36 -0.55 1.46 0.68 0.45 0.79 -0.77

Annual Metrics And Ratios for Spyre Therapeutics

This table displays calculated financial ratios and metrics derived from Spyre Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -23.94% 12.47% -25.30% -100.00% 0.00% 0.00% -87.57% -61.96% -100.00% 0.00%
EBITDA Growth		 -26.35% -93.38% -26.19% -67.26% -76.34% 0.47% 21.38% -31.51% -316.53% 30.50% 21.81%
EBIT Growth		 -27.10% -93.89% -26.32% -64.23% -76.62% -1.35% 19.29% -28.90% -306.89% 33.54% 21.45%
NOPAT Growth		 -27.08% -93.60% -26.34% -64.27% -76.70% -1.43% 19.43% -29.14% -185.80% 13.92% -0.48%
Net Income Growth		 -9.16% -92.10% -25.52% -62.83% -76.45% -3.37% 18.66% -27.38% -304.21% 38.60% 25.39%
EPS Growth		 75.17% 88.44% 18.92% -18.33% -15.02% 37.96% 18.66% -27.38% 0.00% 76.88% 0.00%
Operating Cash Flow Growth		 -49.72% -71.55% -30.65% -30.79% -104.06% -15.35% 29.11% -49.20% -24.66% -57.55% -7.52%
Free Cash Flow Firm Growth		 0.00% -9.46% -66.87% -23.77% -108.46% -21.86% 31.34% -46.74% -65.28% -25.99% -45.09%
Invested Capital Growth		 0.00% -113.52% 136.88% -4,806.71% -68.79% 47.39% -47.28% 41.05% -1,207.92% -20.62% 51.58%
Revenue Q/Q Growth		 0.00% -6.81% 4.75% -27.61% 0.00% 0.00% 24.14% -59.88% -15.94% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -7.65% -4.21% -24.31% -8.54% -0.47% 4.10% 1.38% -16.95% 1.84% -4.01%
EBIT Q/Q Growth		 0.00% -7.77% -4.05% -23.60% -8.95% -1.03% 3.38% 1.51% -16.22% 2.23% -4.40%
NOPAT Q/Q Growth		 0.00% -7.59% -4.08% -23.59% -8.96% -1.08% 3.43% 1.49% -12.41% -7.94% 1.91%
Net Income Q/Q Growth		 0.00% -7.41% -3.81% -23.42% -9.21% -1.53% 3.33% 1.90% -15.07% 3.20% -4.18%
EPS Q/Q Growth		 0.00% 84.71% -141.00% -13.90% -0.41% -18.75% 3.33% 1.90% -1,525.10% -6,004.27% -6,431.43%
Operating Cash Flow Q/Q Growth		 0.00% -25.38% -5.24% -4.30% -16.07% -1.12% -4.14% 1.39% -14.82% -4.07% -4.56%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -8.88% 0.96% -17.60% -1.71% -5.05% 2.10% -9.67% -19.13% 7.12%
Invested Capital Q/Q Growth		 0.00% -313.76% 220.16% -620.76% -33.50% -68.21% 11.37% 11.68% -14.23% 1.79% -32.80%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -184.49% -469.08% -526.30% -1,178.50% 0.00% 0.00% -337.38% -3,569.94% -39,087.70% 0.00% 0.00%
Operating Margin		 -185.95% -473.34% -531.72% -1,169.32% 0.00% 0.00% -350.33% -3,640.23% -27,347.97% 0.00% 0.00%
EBIT Margin		 -185.98% -474.11% -532.53% -1,170.78% 0.00% 0.00% -350.98% -3,640.23% -38,934.88% 0.00% 0.00%
Profit (Net Income) Margin		 -185.62% -468.84% -523.27% -1,140.64% 0.00% 0.00% -351.14% -3,598.75% -38,238.15% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.21% 99.84% 99.99% 100.02% 99.99%
Interest Burden Percent		 99.81% 98.89% 98.26% 97.43% 97.33% 99.27% 99.83% 99.02% 98.22% 90.70% 86.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -529.98% -1,186.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -509.60% -1,173.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 467.41% 1,142.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -62.57% -43.80% -48.08% -75.32% -122.74% -80.93% -58.81% -124.87% -212.49% -52.91% -25.17%
Cash Return on Invested Capital (CROIC)		 -729.98% 0.00% -13,373.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -29.28% -41.51% -45.02% -68.03% 0.00% 0.00% -48.44% -93.64% -167.05% 0.00% 0.00%
Return on Assets (ROA)		 -29.22% -41.05% -44.24% -66.28% 0.00% 0.00% -48.46% -92.58% -164.06% 0.00% 0.00%
Return on Common Equity (ROCE)		 38.49% -18.02% -48.08% -75.32% -122.74% -80.93% -58.81% -124.87% -32.91% -24.29% -18.81%
Return on Equity Simple (ROE_SIMPLE)		 50.86% -34.46% -54.11% -65.77% -130.25% -57.85% -78.39% -166.61% -184.11% -40.17% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.92 -15 -19 -32 -56 -57 -46 -59 -170 -146 -147
NOPAT Margin		 -130.16% -331.34% -372.20% -818.52% 0.00% 0.00% -245.23% -2,548.16% -19,143.58% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -20.38% -13.19% -13.85% -20.10% -30.09% -21.89% -16.60% -32.88% -85.66% -13.16% -1.25%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -117.97% -92.17% -28.20% -20.51%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 97.73% 181.31% 193.39% 324.90% 0.00% 0.00% 145.79% 1,225.03% 4,508.58% 0.00% 0.00%
R&D to Revenue		 188.22% 392.03% 438.33% 944.42% 0.00% 0.00% 304.55% 2,515.20% 24,795.94% 0.00% 0.00%
Operating Expenses to Revenue		 285.95% 573.34% 631.72% 1,269.32% 0.00% 0.00% 450.33% 3,740.23% 27,447.97% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -11 -22 -28 -46 -80 -81 -66 -85 -345 -229 -180
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -22 -27 -46 -81 -80 -63 -83 -346 -241 -188
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 23.20 44.72 66.54 92.15 67.45 69.77 13.75 0.00 3.31 4.54
Price to Tangible Book Value (P/TBV)		 0.00 23.20 44.72 66.54 92.15 67.45 69.77 13.75 0.00 3.31 4.54
Price to Revenue (P/Rev)		 0.00 315.60 432.50 1,154.04 0.00 0.00 312.54 297.06 98.34 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 14,770.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 301.88 422.83 1,134.87 0.00 0.00 307.57 273.14 19.57 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.92 -0.97 -1.00 -1.06 -1.15 -1.09 -1.07 -1.11 -1.24 -1.20 -1.10
Leverage Ratio		 1.07 1.07 1.09 1.14 1.26 1.22 1.21 1.35 1.30 1.21 1.12
Compound Leverage Factor		 1.07 1.06 1.07 1.11 1.23 1.22 1.21 1.34 1.27 1.10 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 68.86% 30.09% 21.79%
Noncontrolling Interests to Total Capital		 161.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.48% 0.00% 0.00%
Common Equity to Total Capital		 -61.51% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -0.34% 69.91% 78.21%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 213.07 233.02 258.13 138.12 256.69 129.94 8.45 -4.66 5.53 22.70
Noncontrolling Interest Sharing Ratio		 161.51% 58.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 84.51% 54.08% 25.27%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.17 16.75 9.77 7.49 4.06 9.11 4.91 4.25 10.68 11.26 13.25
Quick Ratio		 13.10 16.02 8.94 7.28 3.92 8.90 4.66 3.83 10.61 11.16 12.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -12 -20 -25 -51 -63 -43 -63 -104 -131 -191
Operating Cash Flow to CapEx		 -5,279.81% -8,886.79% -3,976.58% -7,628.67% -4,402.95% -1,770.44% -9,374.52% -210,905.26% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.16 0.09 0.08 0.06 0.00 0.00 0.14 0.03 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 17.49 9.77 7.16 4.15 0.00 0.00 3.68 0.60 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.99 -0.40 0.15 -7.01 -12 -6.23 -9.17 -5.41 -71 -85 -41
Invested Capital Turnover		 4.07 3.58 -40.82 -1.13 0.00 0.00 -2.43 -0.32 -0.02 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.99 -3.39 0.55 -7.16 -4.82 5.61 -2.94 3.77 -65 -15 44
Enterprise Value (EV)		 0.00 1,397 2,201 4,412 5,464 9,285 5,764 636 17 750 1,941
Market Capitalization		 0.00 1,461 2,251 4,487 5,536 9,432 5,857 692 87 1,197 2,542
Book Value per Share		 ($37.02) $4.69 $3.02 $2.81 $2.07 $2.92 $1.70 $0.82 ($0.23) $7.04 $7.21
Tangible Book Value per Share		 ($37.02) $4.69 $3.02 $2.81 $2.07 $2.92 $1.70 $0.82 ($0.23) $7.04 $7.21
Total Capital		 36 63 50 67 60 140 84 50 269 518 715
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -33 -64 -50 -75 -72 -146 -93 -56 -339 -603 -757
Capital Expenditures (CapEx)		 0.21 0.21 0.62 0.42 1.49 4.28 0.57 0.04 -0.48 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.62 -1.04 -0.94 -8.08 -16 -13 -14 -8.11 -30 -49 -37
Debt-free Net Working Capital (DFNWC)		 36 62 49 66 56 133 79 48 310 554 719
Net Working Capital (NWC)		 36 62 49 66 56 133 79 48 310 554 719
Net Nonoperating Expense (NNE)		 3.37 6.36 7.86 13 22 24 20 24 169 62 8.51
Net Nonoperating Obligations (NNO)		 -33 -63 -50 -74 -72 -146 -93 -56 -339 -603 -757
Total Depreciation and Amortization (D&A)		 0.09 0.23 0.32 -0.30 -0.40 1.07 2.55 1.64 -1.35 -11 -8.09
Debt-free, Cash-free Net Working Capital to Revenue		 43.07% -22.54% -18.00% -207.84% 0.00% 0.00% -76.74% -348.18% -3,355.19% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 587.72% 1,349.59% 948.36% 1,708.64% 0.00% 0.00% 420.23% 2,043.88% 34,937.92% 0.00% 0.00%
Net Working Capital to Revenue		 587.72% 1,349.59% 948.36% 1,708.64% 0.00% 0.00% 420.23% 2,043.88% 34,937.92% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) ($0.99) $0.00 ($257.60) ($160.02)
Adjusted Weighted Average Basic Shares Outstanding		 599.79K 13.45M 16.72M 28.82M 29.09M 48.02M 49.36M 84.28M 0.00 47.49M 64.42M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) ($0.99) $0.00 ($257.60) ($160.02)
Adjusted Weighted Average Diluted Shares Outstanding		 599.79K 13.45M 16.72M 28.82M 29.09M 48.02M 49.36M 84.28M 0.00 47.49M 64.42M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 599.79K 13.45M 15.13M 20.82M 31.95M 53.37M 65.74M 65.40M 0.00 60.28M 78.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.92 -15 -19 -32 -56 -57 -46 -59 -170 -146 -147
Normalized NOPAT Margin		 -130.16% -331.34% -372.20% -818.52% 0.00% 0.00% -245.23% -2,548.16% -19,143.58% 0.00% 0.00%
Pre Tax Income Margin		 -185.62% -468.84% -523.27% -1,140.64% 0.00% 0.00% -350.39% -3,604.59% -38,241.08% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -17.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Spyre Therapeutics

This table displays calculated financial ratios and metrics derived from Spyre Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 78,540,164.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 78,540,164.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.88
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -127.65% -266.64% -174.88% 77.74% -84.48% 6.55% -6.40% 7.69% 76.80% -11.26% -44.76%
EBIT Growth		 -120.78% -251.27% -155.63% 79.41% -79.41% 7.78% -6.27% 4.84% 77.68% -12.24% -48.20%
NOPAT Growth		 2.23% -139.61% -154.04% 72.28% -202.08% -33.41% -12.13% 5.01% -2.70% 6.66% 14.80%
Net Income Growth		 -119.96% -235.67% -138.07% 82.11% -72.11% 10.90% -2.09% 5.46% 83.80% -11.07% -54.12%
EPS Growth		 117.77% 0.00% 0.00% -98.53% 23.26% 86.18% 17.21% 0.00% 0.00% 0.00% 98.47%
Operating Cash Flow Growth		 -129.61% -71.09% -61.86% -274.02% 14.96% -19.86% -43.63% 25.20% -26.16% -19.84% -39.95%
Free Cash Flow Firm Growth		 347.42% 293.03% 403.77% -286.09% -132.22% -185.34% -184.16% 95.06% -590.80% -196.86% -30.77%
Invested Capital Growth		 -911.21% -1,207.92% -1,536.28% 77.20% -40.30% -20.62% -4.11% -37.20% 64.19% 51.58% 15.62%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 80.72% -64.93% 26.56% 4.66% -59.76% 16.46% 16.39% 17.28% 59.84% -300.59% -8.79%
EBIT Q/Q Growth		 80.98% -62.75% 28.30% 7.25% -65.77% 16.34% 17.38% 16.95% 61.11% -320.66% -9.09%
NOPAT Q/Q Growth		 88.49% -150.39% -4.05% 7.59% -25.47% -10.58% 12.55% 21.71% -35.66% -0.50% 20.17%
Net Income Q/Q Growth		 81.52% -57.53% 30.58% 11.45% -77.74% 18.44% 20.47% 17.99% 69.54% -459.15% -10.36%
EPS Q/Q Growth		 101.51% -1,101.16% 107.86% 149.17% 223.26% -212.26% -3,975.63% 18.08% 69.57% -393.80% 98.76%
Operating Cash Flow Q/Q Growth		 -107.88% 10.29% 8.04% -118.09% 52.74% -26.44% -10.20% -13.58% 20.29% -20.10% -28.70%
Free Cash Flow Firm Q/Q Growth		 -61.15% -22.77% 22.74% -605.41% 93.27% -104.57% -21.04% 70.35% -840.79% 12.09% 46.68%
Invested Capital Q/Q Growth		 72.66% -14.23% -11.68% 34.64% -68.26% 1.79% 3.60% 13.87% 56.08% -32.80% -67.97%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.01% 100.00% 100.07% 100.00% 100.03% 100.00% 99.97% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.98% 93.87% 90.82% 86.77% 93.01% 90.69% 87.34% 86.21% 67.52% 89.75% 90.80%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -281.41% -212.49% -165.81% -102.09% -91.62% -52.91% -47.04% -49.83% -38.08% -25.17% -31.11%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 239.16% -32.91% -0.38% -3.14% 14.42% -24.29% -15.58% -31.12% -22.91% -18.81% -22.71%
Return on Equity Simple (ROE_SIMPLE)		 119.98% 0.00% -239.20% -49.68% -65.64% 0.00% -43.29% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -32 -33 -31 -39 -43 -37 -29 -40 -40 -32
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -19.67% -15.72% -3.98% -2.47% -9.79% -2.85% -1.39% -1.55% 6.36% -3.31% -5.68%
Return On Investment Capital (ROIC_SIMPLE)		 - -17.47% - - - -8.28% -7.77% -6.44% -8.75% -5.60% -4.76%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -41 -67 -48 -45 -74 -62 -51 -43 -17 -70 -76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -69 -51 -48 -77 -64 -54 -45 -18 -72 -78
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 4.33 8.71 3.31 2.98 3.01 3.38 4.54 7.69
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 4.33 8.71 3.31 2.98 3.01 3.38 4.54 7.69
Price to Revenue (P/Rev)		 1,176.10 98.34 1,993.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,350.21 19.57 1,925.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.33 -1.24 -1.19 -1.76 -1.32 -1.20 -1.18 -1.15 -1.15 -1.10 -1.13
Leverage Ratio		 1.43 1.30 1.23 1.87 1.34 1.21 1.19 1.17 1.18 1.12 1.16
Compound Leverage Factor		 1.38 1.22 1.12 1.62 1.25 1.10 1.04 1.01 0.80 1.01 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 68.86% 45.59% 41.62% 47.59% 30.09% 32.29% 34.19% 34.24% 21.79% 23.23%
Noncontrolling Interests to Total Capital		 273.18% 31.48% 62.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -173.18% -0.34% -8.05% 58.38% 52.41% 69.91% 67.71% 65.81% 65.76% 78.21% 76.77%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.89 -1.98 8.49 7.29 6.97 6.44 4.95 4.54 10.30 23.17 24.06
Noncontrolling Interest Sharing Ratio		 184.99% 84.51% 99.77% 96.93% 115.74% 54.08% 66.89% 37.54% 39.83% 25.27% 27.02%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.59 10.68 11.38 19.70 7.32 11.26 8.06 6.49 10.90 13.25 8.97
Quick Ratio		 4.54 10.61 11.32 19.26 7.20 11.16 7.99 6.34 10.51 12.89 8.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 43 33 41 -206 -14 -28 -34 -10 -96 -84 -45
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -62 -71 -79 -52 -87 -85 -82 -71 -31 -41 -69
Invested Capital Turnover		 -0.03 -0.02 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -56 -65 -74 175 -25 -15 -3.24 -19 56 44 13
Enterprise Value (EV)		 1,423 17 1,325 677 1,235 750 564 533 682 1,941 3,376
Market Capitalization		 1,240 87 1,371 947 1,494 1,197 973 903 1,012 2,542 3,962
Book Value per Share		 ($2.43) ($0.23) ($0.89) $5.43 $3.38 $7.04 $5.42 $4.97 $4.95 $7.21 $6.56
Tangible Book Value per Share		 ($2.43) ($0.23) ($0.89) $5.43 $3.38 $7.04 $5.42 $4.97 $4.95 $7.21 $6.56
Total Capital		 142 269 406 374 327 518 483 456 455 715 671
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -204 -339 -485 -426 -414 -603 -565 -527 -486 -757 -741
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -43 -30 -40 -12 -51 -49 -66 -71 -28 -37 -63
Debt-free Net Working Capital (DFNWC)		 161 310 444 414 364 554 499 456 458 719 679
Net Working Capital (NWC)		 161 310 444 414 364 554 499 456 458 719 679
Net Nonoperating Expense (NNE)		 27 31 10 7.93 30 13 7.28 7.36 -29 23 37
Net Nonoperating Obligations (NNO)		 -204 -339 -485 -426 -414 -603 -565 -527 -486 -757 -740
Total Depreciation and Amortization (D&A)		 -0.49 -1.71 -2.42 -3.56 -3.00 -2.42 -2.64 -2.01 -1.35 -2.09 -2.06
Debt-free, Cash-free Net Working Capital to Revenue		 -4,034.35% -3,355.19% -5,840.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 15,282.45% 34,937.92% 64,601.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 15,282.45% 34,937.92% 64,601.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($9.34) ($8.61) $0.72 $0.59 $1.06 ($1.19) ($48.50) ($39.73) ($12.09) ($59.70) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 4.29M 7.34M 36.51M 45.32M 50.89M 47.49M 60.63M 60.70M 60.78M 64.42M 0.00
Adjusted Diluted Earnings per Share		 ($9.34) ($8.61) $0.72 $0.59 $1.06 ($1.19) ($48.50) ($39.73) ($12.09) ($59.70) ($0.74)
Adjusted Weighted Average Diluted Shares Outstanding		 4.29M 7.34M 36.51M 45.32M 50.89M 47.49M 60.63M 60.70M 60.78M 64.42M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($8.61) $0.00 $0.00 $0.00 ($1.19) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.05M 36.15M 40.28M 50.79M 51.43M 60.28M 60.35M 60.40M 77.59M 78.54M 86.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -32 -33 -31 -39 -43 -37 -29 -40 -40 -32
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Spyre Therapeutics, Inc. (SYRE) has been leveraged as a pre-revenue development company. The last four years show large cash inflows from equity financing, ongoing operating deficits, and a balance sheet rich in equity and liquidity but little to no debt. Here are the main trends to know as a retail investor.

  • Equity financing has repeatedly provided large cash runway, with substantial proceeds in recent quarters (for example, about $394.8 million raised in Q4 2024 and about $312.9 million in Q4 2025). Net cash from financing activities in the latest quarter also shows a strong positive inflow (~$312.8 million in Q4 2025).
  • The balance sheet shows a solid liquidity cushion, with cash and short-term investments totaling roughly $486 million in the latest period (about $64.9 million in cash and $421.3 million in short-term investments in Q3 2025).
  • There is little to no traditional debt on the books, reducing near-term financing risk and interest obligations as the company develops its pipeline.
  • Total equity remains substantial and has grown through multiple equity financings, supporting ongoing funding for R&D and operations.
  • Revenue generation is effectively non-existent in the periods shown, reflecting the company’s early-stage, pre-commercial status.
  • Operating expenses (notably R&D and SG&A) remain high relative to revenue, contributing to persistent cash burn.
  • Latest quarter results show a material net loss (Q4 2025 net income around -$62.5 million), highlighting ongoing profitability challenges.
  • Cash burn from operations remains significant, with negative net cash from continuing operating activities in recent quarters (examples around the mid-to-high tens of millions in several periods).
  • Retained earnings sit in a deep deficit (large negative accumulated deficit, e.g., about -$1.06 billion in Q3 2025), underscoring a long path to profitability.
  • Ongoing dilution risk persists due to repeated equity issuances to fund operations, which can dilute existing shareholders' ownership beyond the apparent cash runway.
05/15/26 03:45 PM ETAI Generated. May Contain Errors.

Spyre Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Spyre Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Spyre Therapeutics' net income appears to be on an upward trend, with a most recent value of -$155.20 million in 2025, rising from -$11.30 million in 2015. The previous period was -$208.02 million in 2024. See Spyre Therapeutics' forecast for analyst expectations on what's next for the company.

Spyre Therapeutics' total operating income in 2025 was -$209.56 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $209.56 million

Over the last 10 years, Spyre Therapeutics' total revenue changed from $6.09 million in 2015 to $0.00 in 2025, a change of -100.0%.

Spyre Therapeutics' total liabilities were at $62.55 million at the end of 2025, a 31.0% decrease from 2024, and a 2,352.7% increase since 2015.

In the past 10 years, Spyre Therapeutics' cash and equivalents has ranged from $12.82 million in 2017 to $188.89 million in 2023, and is currently $85.72 million as of their latest financial filing in 2025.

Over the last 10 years, Spyre Therapeutics' book value per share changed from -37.02 in 2015 to 7.21 in 2025, a change of -119.5%.


Related Companies

Financial statements for NASDAQ:SYRE last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Revealed: The World’s First Trillion-Dollar Robot
Jensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...
Weiss Ratings | Sponsoredtc pixel